Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356734 | 1.00 | KLK7 (0.63) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL356995 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29397834 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29397799 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL12606016 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL10983363 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29401353 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL18337922 | 0.92 | FOLH1 (0.56) | KLK7KLK5FOLH1CA1CA2 | |
| SCHEMBL9976419 | 0.92 | FOLH1 (0.56) | KLK7KLK5FOLH1CA1CA2 | |
| SCHEMBL8613001 | 0.89 | FOLH1 (0.52) | KLK7KLK5FOLH1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085848-A1 | NANO-DRUG DELIVERY SYSTEM MODIFIED WITH PHENOLIC ACID OR DIPEPTIDE FOR INCREASING ORAL ABSORBABILITY AND BIOAVAILABILITY, AND USE THEREOF | 四川大学 | 2026-04-30 | — | — | WO | disclosed |
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | L-Base Co., Ltd. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250145577-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | LERCHEN, HANS-GEORG (DE) | 2024-12-26 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4062974-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L BASE CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117083074-A | Pharmaceutical composition for enhancing anticancer effect of anticancer drug | L 基础有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2121725-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | Novo Nordisk Health Care AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-2115001-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| EP-0244836-B1 | TRIPEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | PTMS, DNPEP, VIP | KLK7 777/4885KLK5 952/4885MAPT 2816/4885 |
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | ATG7, CCL11, ATG13 | KLK7 780/4885KLK5 1177/4885MAPT 415/4885 |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | KLK7 2695/4885KLK5 3402/4885MAPT 3874/4885 |
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TP53, BRCA1 | KLK7 2841/4885KLK5 3406/4885MAPT 4327/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | KLK7 90/4885KLK5 397/4885MAPT 1532/4885 |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | FCGRT, FCGR3B, FCGR2A | KLK7 1078/4885KLK5 2244/4885MAPT 1283/4885 |
| US-20250145577-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POLB, SNRPB2, HNRNPA2B1 | KLK7 2742/4885KLK5 3873/4885MAPT 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.